{"organizations": [], "uuid": "c390392669217312695bd06b74e09d11c06c9d8f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-celltrion-receives-eu-approval-for/brief-celltrion-receives-eu-approval-for-trastuzumab-biosimilar-idUSASM000J9E", "country": "US", "domain_rank": 408, "title": "BRIEF-Celltrion Receives EU Approval For Trastuzumab Biosimilar", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-14T03:34:00.000+02:00", "replies_count": 0, "uuid": "c390392669217312695bd06b74e09d11c06c9d8f"}, "author": "", "url": "https://www.reuters.com/article/brief-celltrion-receives-eu-approval-for/brief-celltrion-receives-eu-approval-for-trastuzumab-biosimilar-idUSASM000J9E", "ord_in_thread": 0, "title": "BRIEF-Celltrion Receives EU Approval For Trastuzumab Biosimilar", "locations": [], "entities": {"persons": [], "locations": [{"name": "liechtenstein", "sentiment": "none"}, {"name": "norway", "sentiment": "none"}, {"name": "iceland", "sentiment": "none"}], "organizations": [{"name": "eu approval for trastuzumab biosimilar", "sentiment": "negative"}, {"name": "eu approval for trastuzumab biosimilar reute", "sentiment": "negative"}, {"name": "eu", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Celltrion Inc:\n* CELLTRION RECEIVES EU APPROVAL FOR TRASTUZUMAB BIOSIMILAR\n* CELLTRION-DECISION BY EU MEANS HERZUMA IS APPROVED FOR MARKETING IN 28 MEMBER STATES OF EU, IN ADDITION TO NORWAY, LIECHTENSTEIN AND ICELAND Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-14T03:34:00.000+02:00", "crawled": "2018-02-14T03:45:46.002+02:00", "highlightTitle": ""}